Bolt Biotherapeutics (BOLT) — Cash Flow-to-Debt Ratio
Bolt Biotherapeutics (BOLT) has a Cash Flow-to-Debt Ratio of -0.24x as of December 2025, meaning its operating cash flow of $-7.16 Million could theoretically repay 0% of its total liabilities ($30.24 Million) in one year. Explore Bolt Biotherapeutics long-term investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Bolt Biotherapeutics Cash Flow-to-Debt Ratio (2018–2025)
Historical debt coverage capacity for Bolt Biotherapeutics across 8 annual periods. Also explore Bolt Biotherapeutics balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Bolt Biotherapeutics (2018–2025)
Year-by-year debt coverage analysis for Bolt Biotherapeutics. For market capitalisation and broader financial context, see BOLT stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.32x | $-39.85 Million | $30.24 Million | ▲ +8.8% |
| 2024 | -1.44x | $-61.29 Million | $42.43 Million | ▲ +2.3% |
| 2023 | -1.48x | $-69.53 Million | $47.04 Million | ▼ -8.8% |
| 2022 | -1.36x | $-76.50 Million | $56.30 Million | ▼ -37.2% |
| 2021 | -0.99x | $-57.07 Million | $57.60 Million | ▼ -217.3% |
| 2020 | -0.31x | $-47.31 Million | $151.49 Million | ▼ -11.8% |
| 2019 | -0.28x | $-26.34 Million | $94.29 Million | ▲ +9.7% |
| 2018 | -0.31x | $-9.87 Million | $31.92 Million | — |